Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Ratio (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Equity Ratio data on record, last reported at 0.64 in Q3 2025.

  • For Q3 2025, Equity Ratio rose 22.06% year-over-year to 0.64; the TTM value through Sep 2025 reached 0.64, up 22.06%, while the annual FY2024 figure was 0.59, 48.04% up from the prior year.
  • Equity Ratio reached 0.64 in Q3 2025 per PLX's latest filing, up from 0.64 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.64 in Q3 2025 and bottomed at 0.2 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.23, with a median of 0.31 recorded in 2024.
  • Peak YoY movement for Equity Ratio: tumbled 8057.7% in 2022, then skyrocketed 2089.58% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.08 in 2021, then tumbled by 132.77% to 0.19 in 2022, then surged by 308.46% to 0.4 in 2023, then soared by 48.04% to 0.59 in 2024, then increased by 9.27% to 0.64 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.64 in Q3 2025, 0.64 in Q2 2025, and 0.61 in Q1 2025.